Metabolic

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.

MOTS-c is a mitochondrial-derived peptide that operates as a mitohormone through the Folate-AICAR-AMPK pathway. Under metabolic stress, it translocates to the nucleus to bind stress-response transcription factors (NRF2, ATF1/ATF7), regulating genes involved in metabolism and cellular adaptation.

Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing.

Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.

Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.

First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.

Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.

SS-31 (Elamipretide) is an aromatic-cationic tetrapeptide that selectively binds to cardiolipin in the inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function for enhanced cellular energy production.

Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.